Thursday, January 21, 2021

New trial finds arthritis drug no better than standard care for severe COVID-19

Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, according to results of a new trial.

from Top Health News -- ScienceDaily https://ift.tt/2YfvruZ
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Age-related genetic changes in the blood associated with poor cancer prognosis

Researchers have discovered that expansion of mutant blood cells, a phenomenon linked to aging, can be found in cancerous tumors, and this i...